3/4
12:45 pm
bmrn
BioMarin Pharmaceutical Inc. (BMRN) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
Low
Report
BioMarin Pharmaceutical Inc. (BMRN) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
3/3
07:18 am
bmrn
BioMarin Pharmaceutical (BMRN) had its "overweight" rating reaffirmed by Barclays PLC.
Low
Report
BioMarin Pharmaceutical (BMRN) had its "overweight" rating reaffirmed by Barclays PLC.
3/2
12:11 pm
bmrn
BioMarin Pharmaceutical (BMRN) was given a new $105.00 price target by Loop Capital.
Low
Report
BioMarin Pharmaceutical (BMRN) was given a new $105.00 price target by Loop Capital.
3/1
07:02 pm
bmrn
A Look At BioMarin (BMRN) Valuation After Recent Share Price Rebound [Yahoo! Finance]
Low
Report
A Look At BioMarin (BMRN) Valuation After Recent Share Price Rebound [Yahoo! Finance]
3/1
05:41 pm
bmrn
Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference [Yahoo! Finance]
Low
Report
Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference [Yahoo! Finance]
3/1
04:34 am
bmrn
Canaccord Lifts PT on BioMarin Pharmaceutical (BMRN) to $104 From $98 – Here's Why [Yahoo! Finance]
Low
Report
Canaccord Lifts PT on BioMarin Pharmaceutical (BMRN) to $104 From $98 – Here's Why [Yahoo! Finance]
2/28
02:39 am
bmrn
Bernstein Lifts PT on BioMarin Pharmaceutical (BMRN) to $94 From $90, Here's Why [Yahoo! Finance]
Low
Report
Bernstein Lifts PT on BioMarin Pharmaceutical (BMRN) to $94 From $90, Here's Why [Yahoo! Finance]
2/27
08:22 pm
bmrn
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) [Yahoo! Finance]
Low
Report
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) [Yahoo! Finance]
2/27
08:00 pm
bmrn
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
Low
Report
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
2/26
12:11 pm
bmrn
BioMarin Pharmaceutical (BMRN) was given a new $104.00 price target by Canaccord Genuity Group Inc..
Low
Report
BioMarin Pharmaceutical (BMRN) was given a new $104.00 price target by Canaccord Genuity Group Inc..
2/25
07:04 pm
bmrn
BioMarin Amicus Deal Shifts Rare Disease Portfolio And Valuation Focus [Yahoo! Finance]
Low
Report
BioMarin Amicus Deal Shifts Rare Disease Portfolio And Valuation Focus [Yahoo! Finance]
2/25
12:27 pm
bmrn
BioMarin Pharmaceutical (BMRN) had its price target raised by Sanford C. Bernstein from $90.00 to $94.00. They now have an "outperform" rating on the stock.
Low
Report
BioMarin Pharmaceutical (BMRN) had its price target raised by Sanford C. Bernstein from $90.00 to $94.00. They now have an "outperform" rating on the stock.
2/25
09:40 am
bmrn
Is BioMarin Pharmaceutical (BMRN) Pricing Match Recent Share Rebound And DCF Upside Potential [Yahoo! Finance]
Low
Report
Is BioMarin Pharmaceutical (BMRN) Pricing Match Recent Share Rebound And DCF Upside Potential [Yahoo! Finance]
2/25
09:39 am
bmrn
BioMarin Pharmaceutical (BMRN) had its price target lowered by Guggenheim from $106.00 to $86.00. They now have a "buy" rating on the stock.
Low
Report
BioMarin Pharmaceutical (BMRN) had its price target lowered by Guggenheim from $106.00 to $86.00. They now have a "buy" rating on the stock.
2/25
08:03 am
bmrn
BioMarin Pharmaceutical (BMRN) had its price target lowered by HC Wainwright from $60.00 to $55.00. They now have a "neutral" rating on the stock.
Low
Report
BioMarin Pharmaceutical (BMRN) had its price target lowered by HC Wainwright from $60.00 to $55.00. They now have a "neutral" rating on the stock.
2/24
10:58 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) was given a new $68.00 price target on by analysts at Stifel Nicolaus.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) was given a new $68.00 price target on by analysts at Stifel Nicolaus.
2/24
09:41 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $98.00 to $95.00. They now have an "outperform" rating on the stock.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $98.00 to $95.00. They now have an "outperform" rating on the stock.
2/24
09:17 am
bmrn
BioMarin to Participate in Four Upcoming Investor Conferences in March [Yahoo! Finance]
Low
Report
BioMarin to Participate in Four Upcoming Investor Conferences in March [Yahoo! Finance]
2/24
09:00 am
bmrn
BioMarin to Participate in Four Upcoming Investor Conferences in March
Low
Report
BioMarin to Participate in Four Upcoming Investor Conferences in March
2/24
12:21 am
bmrn
BioMarin Pharmaceutical Inc (BMRN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Low
Report
BioMarin Pharmaceutical Inc (BMRN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
2/23
11:17 pm
bmrn
BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/23
06:43 pm
bmrn
BioMarin Pharmaceutical Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
BioMarin Pharmaceutical Q4 Earnings Call Highlights [Yahoo! Finance]
2/23
05:19 pm
bmrn
BioMarin: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
BioMarin: Q4 Earnings Snapshot [Yahoo! Finance]
2/23
05:08 pm
bmrn
BioMarin Pharmaceutical's (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates [Yahoo! Finance]
Low
Report
BioMarin Pharmaceutical's (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates [Yahoo! Finance]
2/23
04:05 pm
bmrn
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
Low
Report
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results